

Name of the Issue: Rainbow Children’s Medicare Limited

Last Updated on: 13-Nov-25

1 Type of Issue (IPO/FPO) IPO

2 Issue Size (Rs. Cr)  
\* As per Post Offer Report filed with SEBI 1,580.85

3 Grade of issue alongwith name of the rating agency  
Name NA  
Grade NA

4 Subscription Level (Number of times): 12.11079  
\*The above figure is after technical rejection  
Source: Final Post Issue Monitoring Report

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	7.48%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	32.41%
(iii) at the end of 1st FY (March 31, 2023)	35.20%
(iv) at the end of 2nd FY (March 31, 2024)	38.80%
(v) at the end of 3rd FY (March 31, 2025)	39.00%

\* As per the Basis of Allotment  
# QIB Holding not disclosed as reporting for relevant fiscal years have not been completed.  
Source:  
(1) Basis of Allotment  
(2) Reported to the stock exchanges;

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

(Rs. Crore)

Parameters (Consolidated)	1st FY (March 31, 2023)	2nd FY (March 31, 2024)	3rd FY (March 31, 2025)
Income from operations	1,173.57	1,236.56	1,454.51
Net Profit for the period	212.38	214.89	237.59
Paid-up equity share capital	101.50	101.50	101.55
Reserves excluding revaluation reserves	958.4	1,183.7	1,386.99

(1) Financials not disclosed as reporting for the fiscal year has not been completed/ not publicly available

7 Trading Status in the scrip of the issuer  
Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.  
The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2023)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2024)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2025)	Frequently traded

\* Trading status not disclosed as the relevant fiscal year has not been completed.

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2023)	N.A.	N.A.
(ii) at the end of 2nd FY (March 31, 2024)	Adarsh Kanchrla	NA
(iii) at the end of 3rd FY (March 31, 2025)	N.A.	N.A.

As per the website of BSE and NSE  
\* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document - N.A  
(ii) Actual implementation - N.A.  
(iii) Reasons for delay in implementation, if any - N.A.

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

Expenditure Item	Rs. Mn
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited ("CDCEML"), one of our Group Companies, in full	400.00
Capital expenditure towards setting up of new hospitals and purchase of medical	1,700.00
General corporate purposes	561.40

Source: Prospectus

(ii) Actual utilization

Expenditure Item	Rs. Mn
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited	400.00
Capital expenditure towards setting up of new hospitals and purchase of medical	1,700.00
General corporate purposes	576.10

(iii) Reasons for deviation, if any - N.A.

11 Comments of monitoring agency, if applicable

None

12 Pricing Data

Issue Price (Rs.):  
Designated Stock Exchange:  
Listing Date:

542
NSE
5/10/2022

Price parameters	At close of listing day (May 10, 2022)	At close of 30th calendar day from listing day <sup>(1)</sup>	At close of 90th calendar day from listing day <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2023) <sup>(3)</sup>			As at the end of 2nd FY after the listing of the issue (March 31, 2024) <sup>(3)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2025) <sup>(3)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	450.2	467.0	472.6	730.5	886.5	410.0	1,298.0	1,441.5	729.8	1,401.7	1,709.6	1,079.1
Nifty 50	16,240.1	16,356.3	17,397.5	17,359.8	18,887.6	15,183.4	22,326.9	22,493.6	17,398.1	23,519.4	26,277.4	21,281.5
Sectoral Index (NIFTY Healthcare)	7,779.3	7,651.3	8,135.7	7,621.6	8,719.2	7,249.7	12,059.3	12,201.5	7,592.6	13,681.3	15,108.8	11,325.0

- (1) 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day  
(2) 90th calendar day has been taken as listing date plus 89 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day  
(3) High and Low based on intra day prices

13 Basis for Issue Price

Accounting ratio		As disclosed in the offer document dated May 02, 2022	At the end of 1st FY (March 31, 2023)	At the end of 2nd FY (March 31, 2024)	At the end of 3rd FY (March 31, 2025)
EPS	Issuer <sup>(1)</sup> :				
	Consolidated (Basic)	4.36	20.9	21.38	23.4
	Consolidated (Diluted)	4.25	20.9	21.38	23.27
	Peer Group:				
	Apollo Hospitals Enterprise Limited	10.74	58.7	62.49	100.56
	Fortis Healthcare Limited	(1.45)	8.4	7.93	10.26
	Narayana Hrudalaya Limited	(0.70)	29.7	38.68	38.86
	Max Healthcare Institute Limited	(1.59)	11.4	10.89	11.07
	Krishna Institute of Medical Sciences Limited	26.42	45.7	38.75	9.61
	Industry Avg:	6.684	30.78	31.75	34.07
P/E	Issuer <sup>(1)</sup> :				
	Consolidated (Basic)	124.31	34.9	60.71	59.9
	Consolidated (Diluted)	127.53	34.9	60.71	60.2
	Peer Group:				
	Apollo Hospitals Enterprise Limited	428.88	73.4	90.4	65.8
	Fortis Healthcare Limited	N.A. since EPS is negative	31.0	53.0	68.1
	Narayana Hrudalaya Limited	N.A. since EPS is negative	26.1	32.9	43.5
	Max Healthcare Institute Limited	N.A. since EPS is negative	38.8	75.3	99.1
	Krishna Institute of Medical Sciences Limited	54.19	30.7	53.1	66.5
	Industry Avg:	241.535	40.0	60.9	68.6
RoNW (%)	Issuer <sup>(1)</sup> :				
	Consolidated	8.88%	19.90%	16.7%	16.0%
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprise Limited	3.30%	12.9%	13.68%	17.39%
	Fortis Healthcare Limited	-0.75%	7.8%	8.04%	9.34%
	Narayana Hrudalaya Limited	-1.46%	28.4%	31.48%	24.25%
	Max Healthcare Institute Limited	-2.47%	14.9%	13.37%	12.10%
	Krishna Institute of Medical Sciences Limited	23.74%	21.9%	17.73%	19.39%
	Industry Avg:	4.47%	17.20%	16.86%	16.49%
NAV per share based on last balance sheet	Issuer <sup>(1)</sup> :				
	Consolidated	86.07	104.9	124.62	145.25
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprise Limited	320.1	454.2	509.13	601.80
	Fortis Healthcare Limited	81.06	107.3	113.33	121.46
	Narayana Hrudalaya Limited	54.82	104.3	141.18	177.54
	Max Healthcare Institute Limited	58.37	76.3	86.51	96.50
	Krishna Institute of Medical Sciences Limited	111.32	208.6	261.56	302.25
	Industry Avg:	125.13	190.2	222.3	259.9

<sup>(1)</sup> Consolidated data considered

**Notes:**

(1) Sourced from Prospectus dated May 2, 2022.

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares

(ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable for equity shareholders (after adjusting profit impact of dilutive

(iii) Total Income = Revenue from Operations and Other Income

(iv) P/E (Basic/Diluted) - Closing Market Price at the end of relevant fiscal year end on BSE/ Basic/Diluted EPS

(v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year.

(vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year / Number of equity shares outstanding as at the end of fiscal year

14 Any other material information

Date of disclosure	Announcement
9-Feb-23	Rainbow Children's Medicare Limited (Rainbow/Company) on August 29, 2022 has inaugurated a new 55-beds spoke hospital, located at OMR (Sholinganallur) at Chennai. This is Rainbow's first spoke hospital in Chennai. The hospital is designed to provide comprehensive pediatric and obstetrics services. The Company is already operating a 135- beds hub hospital at Guindy, Chennai, Tamil Nadu
1-Mar-23	Company inaugurated a new 100 beds spoke hospital, located at Financial District, Hyderabad, Telangana
15-Apr-23	Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., April 15, 2023, approved appointment of Mr. Sanjeev Sukumaran as the Group Chief Operating Officer (Key Managerial Personnel) with effect from April 15, 2023.
26-Apr-23	Company disclosed copy of credit rating letter received today, from ICRA Limited ('ICRA') assigning credit rating to the Company.
31-May-23	The Board of Directors in their meeting held on May 31, 2023, approved appointment of Mr. Vikas Maheshwari as the Chief Financial Officer (Key Managerial Personnel) of the Company with effect from June 1, 2023.
5-Jul-23	Company received allotment letter from Haryana Sheri Vikas Pradhikaran for the allotment of land parcels located in Sector 44 & Sector 56 of Gurugram, Haryana
30-Oct-23	Company announced re-appointment of Mr. Auri Srinivasa Rao as an independent director of the company
4-Jan-24	Company inaugurated a new bed spoke hospital, located at Central Hyderabad, Himayat Nagar, Hyderabad, Telangana
24-Jan-24	RAINBOW CHILDREN'S MEDICARE LIMITED has informed BSE about appointment of Dr. Adarsh Kancharla as non-independent non-executive director
25-Jan-24	Company announced commencement of a new ~90 bed spoke hospital at Sarjapur, Bengaluru, Karnataka
1-Mar-24	Company announced commencement of a new ~80 bed spoke hospital at Anna Nagar, Chennai, Tamil Nadu.
7-Mar-24	Company announced addition of 50 bed additional block to the existing hospital at Hydernagar, Hyderabad, Telangana
19-May-24	Company announced recommendation of final dividend of Rs. 3 per Equity share for the Financial Year ended March 31, 2024
17-Jul-24	Company announced Allotment of Equity Shares under "Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023"
13-Aug-24	Company announced Appointment of Mr. K V S Subramanyam, Company Secretary in practice as secretarial auditor of the Company for the Financial year 2024-25
27-Oct-24	Company announced Resignation of Group Chief Operating Officer (KMP) of the Company
13-Dec-24	Company intimated resignation of company secretary of the company and appointment of new compliance officer
9-Feb-25	Company announced approval of Employee Stock Option Scheme 2025
1-Mar-25	Company shared further updates on purchase of new land parcels and confirmed that they received necessary approvals
3-Mar-25	Company announced Allotment of Equity Shares under "Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2025"
24-May-25	Company announced recommendation of final dividend of Rs. 3 per Equity share for the Financial Year ended March 31, 2025
9-Jun-25	Announced the appointment of Mr. Srinath Metla as Chief Strategy and Growth Officer and Re-designation of Dr. Preetham Kumar Poddutoor, Senior Consultant - Pediatric Intensive Care, as Director - New Initiatives, Acquisitions and Medical Supply Chain
30-Jun-25	Announced the acquisition of majority stake in Prashanthi Hospital, Warangal
12-Aug-25	Announced the acquisition of majority stake in Pratiksha Hospital, Guwahati
10-Sep-25	Announced the commencement of a new ~100 bed spoke hospital in Rajahmundry, Andhra Pradesh

Source: BSE / NSE website

**Note:** The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com).